Partner with us on the next generation of Cancerlysins™.
We are seeking partners to extend the platform to new tumor-selective antigens — and to advance programs beyond our wholly owned lead.
What we bring to the table.
A validated platform
Cancerlysins™ turn any clinically validated, tumor-selective antigen into an apoptosis-inducing therapeutic — peer-reviewed, independently replicated, and reduced to practice in a lead program.
A de-risked mechanism
No cytotoxic payload, no internalization requirement, and no immune activation — a wide therapeutic window built into the design and borne out by clean non-human-primate safety.
ADC-field pedigree
A team that helped invent Kadcyla®, Elahere™, and Sarclisa®, advancing a lead asset to the IND-enabling stage with a Phase 1 principal investigator engaged.
Where we're looking for partners.
- New tumor-selective targets. Bring a clinically validated antigen; we build the Cancerlysin™ that turns it into a tumor-restricted apoptosis trigger.
- IMV-5 (hematologic malignancy). A platform program advancing on a partnering track.
- Regional and indication-specific collaboration on the broader Cancerlysin™ portfolio.
Start a conversation.
For partnering and business-development inquiries, reach our CEO directly. We respond to every credible inquiry.
ImmuVia, Inc. · 245 First Street, Suite 1800 · Cambridge, MA 02142